We found that ALOC-EO, but not carrier treatment, reduced HB-EGF expression in cultured melanoma cells (Figure 4C,D) and tumor extracts from ALOC-EO-treated tumor-bearing mice (Figure 4C,E). Here, HBEGF is linked to melanoma.